Back to Search Results
Image Place holder

Lynn Moscinski, MD

VICE CHAIR HEMATOPATHOLOGY
Senior Member Hematopathology and Laboratory Medicine
Vice Chair, Hematopathology and Laboratory Medicine

 
Specialty: Pathology
Sub Specialty: Pathology-Hematology
Program: Pathology

Call 1-888-663-3488

Call 1-888-663-3488


Locations:
Overview

Cancer Focus: Hodgkin Lymphoma, Leukemia, MDS, Multiple Myeloma-Plasma Cell Tumor, Myelodysplastic Syndromes (MDS), Non-Hodgkin Lymphoma

Dr. Moscinski is a Senior Member and Chair, Hematopathology and Laboratory Medicine at Moffitt Cancer Center as well as the Chief Academic Officer and Medical Director, Bone Marrow Biopsy Service and the Scientific Director, Liquid Tissue Bank. She holds the title of Professor and Chair, Department of Oncologic Sciences at USF Health. Dr. Moscinski is board certified in Pathology-Hematology and Anatomic/Clinical Pathology. She did her Fellowship at the Hospital of the University of Pennsylvania in Hematopathology and her residency at the University of Colorado Health Sciences Center in Pathology. She earned her medical degree at the Medical College of Wisconsin. Dr. Moscinski’s research interests are in the identification of new biomarkers for diagnosis and risk stratification in myelodysplasia, by both molecular and flow cytometric methods. She is a long term collaborator with both clinicians and scientists at Moffitt working in the field of myeloid disorders, and as the medical director of the Moffitt Liquid Tissue Bank, has a strong interest in improving methods for banking, storage and utilization of human tissue specimens for research.


Education & Training

Fellowship:

  • Hospital of the University of Pennsylvania - Hematopathology

Residency:

  • University of Colorado - Anatomic and Clinical Pathology

Medical School:

  • Medical College of Wisconsin - MD
Participating Trials

If you believe you are eligible for one of these trials or studies, please call
813-745-6100 or toll-free 1-800-679-0775.

Publications

  • Zhang Y, Nguyen L, Lu CM, Wang E, Lauw MIS, Ball S, Dong N, Moscinski L, Chan O, Yun S, Sallman D, Sokol L, Shah B, Knepper T, Lancet J, Komrokji R, Padron E, Kuykendall A, Zhang L. Clinical Response to Upfront Targeted Tyrosine Kinase Inhibitors among Patients with Myeloid/Lymphoid Neoplasms with Eosinophilia and Tyrosine Kinase Gene Fusion. Clin Lymphoma Myeloma Leuk. 2023 Mar.23(3):e150-e163. Pubmedid: 36624015.
  • Zhang L, Shah B, Zhang Y, Tashkandi H, Xiao W, Fernandez-Pol S, Vergara-Lluri M, Hussaini M, Song J, Lancet J, Moscinski L, Yun S, Lu CM, Medeiros LJ, Tang G. Clinicopathologic characteristics, genetic features, and treatment options for acute lymphoblastic leukemia with JAK2 rearrangement-A 10-case study and literature review. Hum Pathol. 2023 Mar. Pubmedid: 36958463.
  • Mora LB, Hough M, Moscinski L, Gomez J, Coppola D. Incidental Gastric Langerhans Cell Histiocytosis and Synchronous Adenocarcinoma of the Colon: An Interesting Case Report and Literature Review. Cancer Diagn Progn. 2023 Jan.3(1):102-106. Pubmedid: 36632587. Pmcid: PMC9801445.
  • Song J, Zhang H, Dong N, Zhang X, Hussaini M, Jain A, Moscinski L, Shain K, Baz R, Alsina M, Nishihori T, Zhang L. The Application of NextGen Sequencing in the Diagnosis of Myeloid Neoplasms in Myeloma Patients With Cytopenia. Clin Lymphoma Myeloma Leuk. 2022 Jun.22(6):e414-e426. Pubmedid: 34998786.
  • Nguyen L, Zhang X, Roberts E, Yun S, McGraw K, Abraham I, Song J, Braswell D, Qin D, Sallman DA, Lancet JE, List AF, Moscinski LC, Padron E, Zhang L. Comparison of mutational profiles and clinical outcomes in patients with acute myeloid leukemia with mutated RUNX1 versus acute myeloid leukemia with myelodysplasia-related changes with mutated RUNX1. Leuk Lymphoma. 2020 Jun.61(6):1395-1405. Pubmedid: 32091281. Pmcid: PMC7269833.
  • Song J, Hussaini M, Qin D, Zhang X, Shao H, Zhang L, Gajzer D, Basra P, Moscinski L, Zhang H. Comparison of SF3B1/DNMT3A Comutations With DNMT3A or SF3B1 Mutation Alone in Myelodysplastic Syndrome and Clonal Cytopenia of Undetermined Significance. Am J Clin Pathol. 2020 Jun.154(1):48-56. Pubmedid: 32112088.
  • Yun S, Sharma R, Chan O, Vincelette ND, Sallman DA, Sweet K, Padron E, Komrokji R, Lancet JE, Abraham I, Moscinski LC, Cleveland JL, List AF, Zhang L. Prognostic significance of MYC oncoprotein expression on survival outcome in patients with acute myeloid leukemia with myelodysplasia related changes (AML-MRC). Leuk Res. 2019 Sep.84:106194. Pubmedid: 31357093. Pmcid: PMC7375354.
  • Horna P, Moscinski LC, Sokol L, Shao H. Naïve/memory T-cell phenotypes in leukemic cutaneous T-cell lymphoma: Putative cell of origin overlaps disease classification. Cytometry B Clin Cytom. 2019 May.96(3):234-241. Pubmedid: 30328260. Pmcid: PMC7703846.
  • Zhao X, Ren Y, Lawlor M, Shah BD, Park PMC, Lwin T, Wang X, Liu K, Wang M, Gao J, Li T, Xu M, Silva AS, Lee K, Zhang T, Koomen JM, Jiang H, Sudalagunta PR, Meads MB, Cheng F, Bi C, Fu K, Fan H, Dalton WS, Moscinski LC, Shain KH, Sotomayor EM, Wang GG, Gray NS, Cleveland JL, Qi J, Tao J. BCL2 Amplicon Loss and Transcriptional Remodeling Drives ABT-199 Resistance in B Cell Lymphoma Models. Cancer Cell. 2019 May.35(5):752-766.e9. Pubmedid: 31085176. Pmcid: PMC6945775.
  • Jiang H, Lwin T, Zhao X, Ren Y, Li G, Moscinski L, Shah B, Tao J. Venetoclax as a single agent and in combination with PI3K-MTOR1/2 kinase inhibitors against ibrutinib sensitive and resistant mantle cell lymphoma. Brit J Haematol. 2019 Jan.184(2):298-302. Pubmedid: 29383700. Pmcid: PMC6066460.
  • Song J, Moscinski L, Zhang H, Zhang X, Hussaini M. Does SF3B1/TET2 Double Mutation Portend Better or Worse Prognosis Than Isolated SF3B1 or TET2 Mutation?. Cancer Genomics Proteomics. 2019 Jan.16(1):91-98. Pubmedid: 30587503. Pmcid: PMC6348401.
  • McGraw KL, Nguyen J, Al Ali NH, Komrokji RS, Sallman D, Zhang X, Song J, Padron E, Lancet JE, Moscinski LC, List AF, Zhang L. Association of EZH2 protein expression by immunohistochemistry in myelodysplasia related neoplasms with mutation status, cytogenetics and clinical outcomes. Brit J Haematol. 2019 Feb.184(3):450-455. Pubmedid: 29359794. Pmcid: PMC7771337.
  • Sekeres MA, Gore SD, Stablein DM, DiFronzo N, Abel GA, DeZern AE, Troy JD, Rollison DE, Thomas JW, Waclawiw MA, Liu JJ, Al Baghdadi T, Walter MJ, Bejar R, Gorak EJ, Starczynowski DT, Foran JM, Cerhan JR, Moscinski LC, Komrokji RS, Deeg HJ, Epling-Burnette PK. The National MDS Natural History Study: design of an integrated data and sample biorepository to promote research studies in myelodysplastic syndromes. Leuk Lymphoma. 2019 Dec.60(13):3161-3171. Pubmedid: 31111762. Pmcid: PMC7757428.
  • Padron E, Ball MC, Teer JK, Painter JS, Yoder SJ, Zhang C, Zhang L, Moscinski LC, Rollison DE, Gore SD, Bejar R, Walter MJ, Sekeres MA, Komrokji RS, Epling-Burnette PK. Germ line tissues for optimal detection of somatic variants in myelodysplastic syndromes. Blood. 2018 May.131(21):2402-2405. Pubmedid: 29661788. Pmcid: PMC5969383.
  • Ren Y, Bi C, Zhao X, Lwin T, Wang C, Yuan J, Silva AS, Shah BD, Fang B, Li T, Koomen JM, Jiang H, Chavez JC, Pham L, Sudalagunta PR, Wan L, Wang X, Dalton WS, Moscinski LC, Shain KH, Vose J, Cleveland JL, Sotomayor EM, Fu K, Tao J. PLK1 stabilizes a MYC-dependent kinase network in aggressive B cell lymphomas. J Clin Invest. 2018 Dec.128(12):5517-5530. Pubmedid: 30260324. Pmcid: PMC6264635.
  • Kharfan-Dabaja MA, Komrokji RS, Zhang Q, Kumar A, Tsalatsanis A, Perkins J, Nishihori T, Field T, Al Ali N, Mishra A, Sallman D, Salem KZ, Zhang L, Moscinski L, Fernandez HF, Lancet J, List A, Anasetti C, Padron E. TP53 and IDH2 Somatic Mutations Are Associated With Inferior Overall Survival After Allogeneic Hematopoietic Cell Transplantation for Myelodysplastic Syndrome. Clin Lymphoma Myeloma Leuk. 2017 Nov.17(11):753-758. Pubmedid: 28687222. Pmcid: PMC5675815.
  • Song J, Hussaini M, Zhang H, Shao H, Qin D, Zhang X, Ma Z, Hussnain Naqvi SM, Zhang L, Moscinski LC. Comparison of the Mutational Profiles of Primary Myelofibrosis, Polycythemia Vera, and Essential Thrombocytosis. Am J Clin Pathol. 2017 May.147(5):444-452. Pubmedid: 28419183. Pmcid: PMC5402718.
  • Talati C, Zhang L, Shaheen G, Kuykendall A, Ball M, Zhang Q, Lancet JE, Zuckerman KS, List AF, Komrokji R, Moscinski L, Padron E. Monocyte subset analysis accurately distinguishes CMML from MDS and is associated with a favorable MDS prognosis. Blood. 2017 Mar.129(13):1881-1883. Pubmedid: 28159734.
  • Zhao X, Lwin T, Silva A, Shah B, Tao J, Fang B, Zhang L, Fu K, Bi C, Li J, Jiang H, Meads MB, Jacobson T, Silva M, Distler A, Darville L, Zhang L, Han Y, Rebatchouk D, Di Liberto M, Moscinski LC, Koomen JM, Dalton WS, Shain KH, Wang M, Sotomayor E, Tao J. Unification of de novo and acquired ibrutinib resistance in mantle cell lymphoma. Nat Commun. 2017 Apr.8:14920. Pubmedid: 28416797. Pmcid: PMC5399304.
  • Suleiman Y, Dalia S, Liu JJ, Bowers JW, Padron E, Lancet JE, Fulp W, Moscinski LC, Komrokji RS, Zuckerman KS, Zhang L. Clinical prognostic factors and outcomes of essential thrombocythemia when transformed to myelodysplastic syndromes and acute myeloid leukemia. Leuk Res. 2016 Mar.42:52-58. Pubmedid: 26894965.
  • McGraw KL, Nguyen J, Komrokji RS, Sallman D, Al Ali NH, Padron E, Lancet JE, Moscinski LC, List AF, Zhang L. Immunohistochemical pattern of p53 is a measure of TP53 mutation burden and adverse clinical outcome in myelodysplastic syndromes and secondary acute myeloid leukemia. Haematologica. 2016 Aug.101(8):e320-e323. Pubmedid: 27081179. Pmcid: PMC4967580.
  • Zhang X, Sokol L, Bennett JM, Moscinski LC, List A, Zhang L. T-cell large granular lymphocyte proliferation in myelodysplastic syndromes: Clinicopathological features and prognostic significance. Leuk Res. 2016 Apr.43:18-23. Pubmedid: 26927701.
  • Horna P, Kurant D, Sokol L, Sotomayor EM, Moscinski L, Glass LF. Flow cytometric identification of immunophenotypically aberrant T-cell clusters on skin shave biopsy specimens from patients with mycosis fungoides. Am J Clin Pathol. 2015 Jun.143(6):785-796. Pubmedid: 25972320.
  • Tao J, Zhang X, Lancet J, Bennett JM, Cai L, Papenhausen P, Moscinski L, Zhang L. Concurrence of B-lymphoblastic leukemia and myeloproliferative neoplasm with copy neutral loss of heterozygosity at chromosome 1p harboring a MPL W515S mutation. Cancer Genet. 2015 Feb.207(10-12):489-494. Pubmedid: 25453399.
  • Hu X, Laguerre V, Packert D, Nakasone A, Moscinski L. A Simple and Efficient Method for Preparing Cell Slides and Staining without Using Cytocentrifuge and Cytoclips. Int J Cell Biol. 2015 Dec.2015:813216. Pubmedid: 26664363. Pmcid: PMC4664808.
  • Peker D, Padron E, Bennett JM, Zhang X, Horna P, Epling-Burnette PK, Lancet JE, Pinilla-Ibarz J, Moscinski L, List AF, Komrokji RS, Zhang L. A close association of autoimmune-mediated processes and autoimmune disorders with chronic myelomonocytic leukemia: observation from a single institution. Acta Haematol. 2015 Apr.133(2):249-256. Pubmedid: 25413011.
  • Horna P, Zhang L, Sotomayor EM, Lancet JE, Moscinski LC. Diagnostic immunophenotype of acute promyelocytic leukemia before and early during therapy with all-trans retinoic acid. Am J Clin Pathol. 2014 Oct.142(4):546-552. Pubmedid: 25239423. Pmcid: PMC5744863.
  • Horna P, Deaver DM, Qin D, Moscinski LC, Sotomayor EM, Glass LF, Sokol L. Quantitative flow cytometric identification of aberrant T cell clusters in erythrodermic cutaneous T cell lymphoma. Implications for staging and prognosis. J Clin Pathol. 2014 May.67(5):431-436. Pubmedid: 24319102.
  • Horna P, Pantazopoulos P, Lancet JE, Moscinski LC, Zhang L. Prominent hematogone hyperplasia in BCR-ABL1-positive chronic myelogenous leukemia: mimicking recurrent B-lymphoid blast crisis. Leuk Lymphoma. 2014 Aug.55(8):1952-1954. Pubmedid: 24304373.
  • Mailloux AW, Zhang L, Moscinski L, Bennett JM, Yang L, Yoder SJ, Bloom G, Wei C, Wei S, Sokol L, Loughran TP, Epling-Burnette PK. Fibrosis and subsequent cytopenias are associated with basic fibroblast growth factor-deficient pluripotent mesenchymal stromal cells in large granular lymphocyte leukemia. J Immunol. 2013 Oct.191(7):3578-3593. Pubmedid: 24014875. Pmcid: PMC4346227.
  • Lwin T, Zhao X, Cheng F, Zhang X, Huang A, Shah B, Zhang Y, Moscinski LC, Choi YS, Kozikowski AP, Bradner JE, Dalton WS, Sotomayor E, Tao J. A microenvironment-mediated c-Myc/miR-548m/HDAC6 amplification loop in non-Hodgkin B cell lymphomas. J Clin Invest. 2013 Nov.123(11):4612-4626. Pubmedid: 24216476. Pmcid: PMC3809771.
  • Zhang Y, Zhang L, Jin X, Zhao H, Hao X, Peker D, Wei S, Sokol L, Moscinski L. Bone marrow involvement as initial presentation of CD8 cytotoxic peripheral T-cell lymphoma with CD20 coexpression and relatively indolent clinical course. Leuk Lymphoma. 2013 May.54(5):1113-1116. Pubmedid: 23035635.
  • Setoodeh R, Schwartz S, Papenhausen P, Zhang L, Sagatys EM, Moscinski LC, Shao H. Double-hit mantle cell lymphoma with MYC gene rearrangement or amplification: a report of four cases and review of the literature. Int J Clin Exp Pathol. 2013 Jul.6(2):155-167. Pubmedid: 23330001. Pmcid: PMC3544229.
  • Zhang L, Sotomayor EM, Papenhausen PR, Shao H, Moscinski LC, Sandin RL, Caceres G, Valenica H, Malafa M, List AF, Sokol L. Unusual concurrence of T-cell large granular lymphocytic leukemia with Franklin disease (gamma heavy chain disease) manifested with massive splenomegaly. Leuk Lymphoma. 2013 Jan.54(1):205-208. Pubmedid: 22694793.
  • Trimaldi J, Carballido EM, Bowers JW, Anguiano AL, Zhang ZJ, Shah BD, Bruno S, List AF, Moscinski LC, Grady T, Agosti SJ, Kang L, Zhang L. B-lymphoblastic leukemia/lymphoma associated with t(8;13)(p11;q12)/ ZMYM2 (ZNF198)-FGFR1 : rare case and review of the literature. Acta Haematol. 2013 Dec.130(3):127-134. Pubmedid: 23594707.
  • Zhang X, Zhao X, Fiskus W, Lin J, Lwin T, Rao R, Zhang Y, Chan JC, Fu K, Marquez VE, Chen-Kiang S, Moscinski LC, Seto E, Dalton WS, Wright KL, Sotomayor E, Bhalla K, Tao J. Coordinated silencing of MYC-mediated miR-29 by HDAC3 and EZH2 as a therapeutic target of histone modification in aggressive B-Cell lymphomas. Cancer Cell. 2012 Oct.22(4):506-523. Pubmedid: 23079660. Pmcid: PMC3973134.
  • Zhang X, Chen X, Lin J, Lwin T, Wright G, Moscinski LC, Dalton WS, Seto E, Wright K, Sotomayor E, Tao J. Myc represses miR-15a/miR-16-1 expression through recruitment of HDAC3 in mantle cell and other non-Hodgkin B-cell lymphomas. Oncogene. 2012 Jun.31(24):3002-3008. Pubmedid: 22002311. Pmcid: PMC3982396.
  • Mathew RA, Bennett JM, Liu JJ, Komrokji RS, Lancet JE, Naghashpour M, Messina JL, List AF, Moscinski LC, Zhang L. Cutaneous manifestations in CMML: Indication of disease acceleration or transformation to AML and review of the literature. Leuk Res. 2012 Jan.36(1):72-80. Pubmedid: 21782240.
  • Zhang L, Bennett JM, Zhang X, Moscinski L, Ibarz-Pinilla J, List AF, Komrokji R. Uncommon of the uncommon: low-grade myelodysplastic syndrome evolving into chronic myelogenous leukemia. J Clin Oncol. 2011 May.29(15):e434-e436. Pubmedid: 21149648.
  • Hu X, Moscinski LC. Cdc2: a monopotent or pluripotent CDK?. Cell Proliferat. 2011 Jun.44(3):205-211. Pubmedid: 21535261. Pmcid: PMC6496858.
  • Lin J, Lwin T, Zhao JJ, Tam W, Choi YS, Moscinski LC, Dalton WS, Sotomayor EM, Wright KL, Tao J. Follicular dendritic cell-induced microRNA-mediated upregulation of PRDM1 and downregulation of BCL-6 in non-Hodgkin's B-cell lymphomas. Leukemia. 2011 Jan.25(1):145-152. Pubmedid: 20966935. Pmcid: PMC3083119.
  • Naghashpour M, Setoodeh R, Moscinski L, Bergier G, McCardle T, Glass F, Sokol L. Nonnecrobiotic necrobiotic xanthogranuloma as an initial manifestation of paraproteinemia and small lymphocytic lymphoma in a patient with Sjögren syndrome. Am J Dermatopathxxx. 2011 Dec.33(8):855-857. Pubmedid: 22042261.
  • Powers JJ, Dubovsky JA, Epling-Burnette PK, Moscinski L, Zhang L, Mustjoki S, Sotomayor EM, Pinilla-Ibarz JA. A molecular and functional analysis of large granular lymphocyte expansions in patients with chronic myelogenous leukemia treated with tyrosine kinase inhibitors. Leuk Lymphoma. 2011 Apr.52(4):668-679. Pubmedid: 21271862. Pmcid: PMC4487410.
  • Sokol L, Caceres G, Volinia S, Alder H, Nuovo GJ, Liu CG, McGraw K, Clark JA, Sigua CA, Chen DT, Moscinski L, Croce CM, List AF. Identification of a risk dependent microRNA expression signature in myelodysplastic syndromes. Brit J Haematol. 2011 Apr.153(1):24-32. Pubmedid: 21332710. Pmcid: PMC4294220.
  • Johns ME, Moscinski LC, Sokol L. Phenytoin-associated lymphoadenopathy mimicking a peripheral T-cell lymphoma. Mediterr J Hematol Infect Dis. 2010 Sep.2(2):e2010028. Pubmedid: 21415974. Pmcid: PMC3033141.
  • Naghashpour M, Lancet J, Moscinski L, Zhang L. Mixed phenotype acute leukemia with t(11;19)(q23;p13.3)/ MLL-MLLT1(ENL), B/T-lymphoid type: A first case report. Am J Hematol. 2010 Jun.85(6):451-454. Pubmedid: 20513125.
  • Mourad AR, Kharfan-Dabaja MA, Benson K, Moscinski LC, Baz RC. Leptomeningeal myeloma as the sole manifestation of relapse: an unusual presentation. Am J Med Sci. 2010 Jan.339(1):81-82. Pubmedid: 19875952.
  • Pal R, Monaghan SA, Hassett AC, Mapara MY, Schafer P, Roodman GD, Ragni MV, Moscinski L, List A, Lentzsch S. Immunomodulatory derivatives induce PU.1 down-regulation, myeloid maturation arrest, and neutropenia. Blood. 2010 Jan.115(3):605-614. Pubmedid: 19965623.
  • Lwin T, Lin J, Choi YS, Zhang X, Moscinski LC, Wright KL, Sotomayor EM, Dalton WS, Tao J. Follicular dendritic cell-dependent drug resistance of non-Hodgkin lymphoma involves cell adhesion-mediated Bim down-regulation through induction of microRNA-181a. Blood. 2010 Dec.116(24):5228-5236. Pubmedid: 20841506. Pmcid: PMC3012540.
  • Wiranowska M, Ladd S, Moscinski LC, Hill B, Haller E, Mikecz K, Plaas A. Modulation of hyaluronan production by CD44 positive glioma cells. Int J Cancer. 2010 Aug.127(3):532-542. Pubmedid: 19957333. Pmcid: PMC3962665.
  • Zhao JJ, Lin J, Lwin T, Yang H, Guo J, Kong W, Dessureault S, Moscinski LC, Rezania D, Dalton WS, Sotomayor E, Tao J, Cheng JQ. microRNA expression profile and identification of miR-29 as a prognostic marker and pathogenetic factor by targeting CDK6 in mantle cell lymphoma. Blood. 2010 Apr.115(13):2630-2639. Pubmedid: 20086245. Pmcid: PMC2852365.
  • Lwin T, Crespo LA, Wu A, Dessureault S, Shu HB, Moscinski LC, Sotomayor E, Dalton WS, Tao J. Lymphoma cell adhesion-induced expression of B cell-activating factor of the TNF family in bone marrow stromal cells protects non-Hodgkin's B lymphoma cells from apoptosis. Leukemia. 2009 Jan.23(1):170-177. Pubmedid: 18843286.
  • Montenegro DE, Franklin T, Moscinski LC, Zuckerman KS, Hu XT. TGFbeta inhibits GM-CSF-induced phosphorylation of ERK and MEK in human myeloid leukaemia cell lines via inhibition of phosphatidylinositol 3-kinase (PI3-k). Cell Proliferat. 2009 Feb.42(1):1-9. Pubmedid: 19143758. Pmcid: PMC3928791.
  • Epling-Burnette PK, Sokol L, Chen X, Bai F, Zhou J, Blaskovich MA, Zou J, Painter JS, Edwards TD, Moscinski L, Yoder JA, Djeu JY, Sebti S, Loughran TP, Wei S. Clinical improvement by farnesyltransferase inhibition in NK large granular lymphocyte leukemia associated with imbalanced NK receptor signaling. Blood. 2008 Dec.112(12):4694-4698. Pubmedid: 18791165. Pmcid: PMC2597136.
  • Lwin T, Hazlehurst LA, Dessureault S, Lai R, Bai W, Sotomayor E, Moscinski LC, Dalton WS, Tao J. Cell adhesion induces p27Kip1-associated cell-cycle arrest through down-regulation of the SCFSkp2 ubiquitin ligase pathway in mantle-cell and other non-Hodgkin B-cell lymphomas. Blood. 2007 Sep.110(5):1631-1638. Pubmedid: 17502456. Pmcid: PMC1975846.
  • Lancet JE, List AF, Moscinski LC. Treatment of deletion 5q acute myeloid leukemia with lenalidomide. Leukemia. 2007 Mar.21(3):586-588. Pubmedid: 17230228.
  • Burnette PK, Bai F, Painter JS, Rollison DE, Salih HR, Krusch M, ZouJ, Ku E, Zhong B, Boulware D, Moscinski L, Wei S, Djeu JY, List AF. Reduced natural killer (NK) function associated with high-risk myelodysplastic syndrome (MDS) and reduced expression of activating NK receptors. Blood. 2007 Jun.109(11):4816-4824. Pubmedid: 17341666. Pmcid: PMC1885518.
  • Lwin T, Hazlehurst LA, Li Z, Dessureault S, Sotomayor E, Moscinski LC, Dalton WS, Tao J. Bone marrow stromal cells prevent apoptosis of lymphoma cells by upregulation of anti-apoptotic proteins associated with activation of NF-kappaB (RelB/p52) in non-Hodgkin's lymphoma cells. Leukemia. 2007 Jul.21(7):1521-1531. Pubmedid: 17476277.
  • Wu J, Cantor A, Moscinski L. beta2 Integrins are characteristically absent in acute promyelocytic leukemia and rapidly upregulated in vivo upon differentiation with all-trans retinoic acid. Leuk Res. 2007 Jan.31(1):49-57. Pubmedid: 16764927.
  • Cualing HD, Zhong E, Moscinski L. "Virtual flow cytometry" of immunostained lymphocytes on microscopic tissue slides: iHCFlow tissue cytometry. Cytometry B Clin Cytom. 2007 Jan.72(1):63-76. Pubmedid: 17133379.
  • Hu X, Cui D, Moscinski LC, Zhang X, Maccachero V, Zuckerman KS. TGFbeta regulates the expression and activities of G2 checkpoint kinases in human myeloid leukemia cells. Cytokine. 2007 Feb.37(2):155-162. Pubmedid: 17459720.
  • George P, Bali P, Annavarapu S, Scuto A, Fiskus W, Guo F, Sigua C, Sondarva G, Moscinski L, Atadja P, Bhalla K. Combination of the histone deacetylase inhibitor LBH589 and the hsp90 inhibitor 17-AAG is highly active against human CML-BC cells and AML cells with activating mutation of FLT-3. Blood. 2005 Feb.105(4):1768-1776. Pubmedid: 15514006.
  • George P, Bali P, Cohen P, Tao J, Guo F, Sigua C, Vishvanath A, Fiskus W, Scuto A, Annavarapu S, Moscinski L, Bhalla K. Cotreatment with 17-allylamino-demethoxygeldanamycin and FLT-3 kinase inhibitor PKC412 is highly effective against human acute myelogenous leukemia cells with mutant FLT-3. Cancer Res. 2004 May.64(10):3645-3652. Pubmedid: 15150124.
  • Johnson J, Moscinski L, Zuckerman K. Value of positron emission tomography scan in staging cancers, and an unusual presentation of acute myeloid leukemia. Case 3. Acute myeloid leukemia presenting with lytic bone lesions. J Clin Oncol. 2004 Jul.22(14):2968-2970. Pubmedid: 15254066.
  • Bali P, George P, Cohen P, Tao J, Guo F, Sigua C, Vishvanath A, Scuto A, Annavarapu S, Fiskus W, Moscinski L, Atadja P, Bhalla K. Superior activity of the combination of histone deacetylase inhibitor LAQ824 and the FLT-3 kinase inhibitor PKC412 against human acute myelogenous leukemia cells with mutant FLT-3. Clin Cancer Res. 2004 Aug.10(15):4991-4997. Pubmedid: 15297399.
  • Guo F, Sigua C, Tao J, Bali P, George P, Li Y, Wittmann S, Moscinski L, Atadja P, Bhalla K. Cotreatment with histone deacetylase inhibitor LAQ824 enhances Apo-2L/tumor necrosis factor-related apoptosis inducing ligand-induced death inducing signaling complex activity and apoptosis of human acute leukemia cells. Cancer Res. 2004 Apr.64(7):2580-2589. Pubmedid: 15059915.
  • Eason D, LeBron C, Coppola D, Moscinski L, Livingston S, Sutton E, Blanck G. Development of CD30+ lymphoproliferative disease in mice lacking interferon regulatory factor-1. Oncogene. 2003 Sep.22(40):6166-6176. Pubmedid: 13679855.
  • Hazlehurst L, Enkemann S, Beam C, Argilagos R, Painter J, Shain K, Saporta S, Boulware L, Moscinski L, Alsina M, Dalton W. Genotypic and phenotypic comparisons of de novo and acquired melphalan resistance in an isogenic multiple myeloma cell line model. Cancer Res. 2003 Nov.63(22):7900-7906. Pubmedid: 14633719.
  • Nimmanapalli R, Fuino L, Bali P, Gasparetto M, Glozak M, Tao J, Moscinski L, Smith C, Wu J, Jove R, Atadja P, Bhalla K. Histone deacetylase inhibitor LAQ824 both lowers expression and promotes proteasomal degradation of Bcr-Abl and induces apoptosis of imatinib mesylate-sensitive or -refractory chronic myelogenous leukemia-blast crisis cells. Cancer Res. 2003 Aug.63(16):5126-5135. Pubmedid: 12941844.
  • McIlwain L, Sokol L, Moscinski L, Saba H. Acute myeloid leukemia mimicking primary testicular neoplasm. Presentation of a case with review of literature. Eur J Haematol. 2003 Apr.70(4):242-245. Pubmedid: 12656749.
  • Huang M, Dorsey JF, Epling-Burnette PK, Nimmanapalli R, Landowski TH, Mora LB, Niu G, Sinibaldi D, Bai F, Kraker A, Yu H, Moscinski L, Wei S, Djeu J, Dalton WS, Bhalla K, Loughran TP, Wu J, Jove R. Inhibition of Bcr-Abl kinase activity by PD180970 blocks constitutive activation of Stat5 and growth of CML cells. Oncogene. 2002 Dec.21(57):8804-8816. Pubmedid: 12483533.
  • Nordquist LT, Saba HI, Moscinski LC. IgM Myeloma: An IgM Gammopathy Distinct from Waldenstrom's Macroglobulinemia. Hematology. 2001 Jan.6(1):53-58. Pubmedid: 27419604.
  • Hu X, Janssen WE, Moscinski LZC, Bryington M, Dangsupa A, Rezai-Zadeh N, Babbin BA, Zuckerman KS. An IkappaBalpha inhibitor causes leukemia cell death through a p38 MAP kinase-dependent, NF-kappaB-independent mechanism. Cancer Res. 2001 Aug.61(16):6290-6296. Pubmedid: 11507084.
  • Hu X, Moscinski L, Valkov N, Fisher A, Hill R, Zuckerman K. Prolonged activation of the mitogen-activated protein kinase pathway is required for macrophage-like differentiation of a human myeloid leukemic cell line. Cell Growth Differ. 2000 Apr.11(4):191-200. Pubmedid: 10775036.
  • Mora L, Moscinski L, Diaz J, Blair P, Cantor A, Pow-Sang J. Stage B Prostate Cancer: Correlation of DNA Ploidy Analysis With Histological and Clinical Parameters. Cancer Control. 1999 Nov.6(6):587-591. Pubmedid: 10756390.
  • Falcone R, Landowski TH, Oshiro MM, Turkson J, Levitzki A, Savino R, Ciliberto G, Moscinski L, Fernandez-Luna JL, Nunez G, Dalton WS, Jove R. Constitutive activation of Stat3 signaling confers resistance to apoptosis in human U266 myeloma cells. Immunity. 1999 Jan.10(1):105-115. Pubmedid: 10023775.
  • Hu X, Moscinski LC, Zuckerman KS. Transforming growth factor beta inhibits growth of more differentiated myeloid leukemia cells and retinoblastoma protein phosphorylation at serine 795. Exp Hematol. 1999 Apr.27(4):605-614. Pubmedid: 10210318.
  • Hu X, Moscinski L, Hill B, Chen Q, Wu J, Fisher A, Zuckerman K. Characterization of a unique factor-independent variant derived from human factor-dependent TF-1 cells: a transformed event. Leuk Res. 1998 Sep.22(9):817-826. Pubmedid: 9716013.
  • Moscinski LC. Laboratory and Bone Marrow Evaluation in Patients With Cancer. Cancer Control. 1998 Mar.5(2 Suppl 1):12-16. Pubmedid: 10762461.
  • Garcia E, Sandin R, Greene J, Baekey P, Walling A, Letson G, Choy J, Nicosia S, Moscinski L. Infections of the leg which mimic malignancy. Infect Med. 1998.15(8):557-567.
  • Quiroz ES, Castellano CM, Greene JN, Sandin RL, Moscinski LC. Toxoplasmic Lymphadenopathy Clinically Presenting as Lymphoma. Cancer Control. 1997 Oct.4(5):434-439. Pubmedid: 10763053.
  • Papenhausen PR, Moscinski LC, Binnie CG. Cytogenetic and Molecular Evaluation in Myelodysplastic Syndrome and in Acute and Chronic Leukemia. Cancer Control. 1997 Oct.4(5):389-398. Pubmedid: 10763046.
  • Moscinski LC. Leukemia: A Transition From Basic Science to Clinical Practice. Cancer Control. 1997 Oct.4(5):383-385. Pubmedid: 10763045.
  • Ballester O, Moscinski L, Fields K, Hiemenz J, Zorsky P, Goldstein S, Saba H, Spiers A, Kronish L, Sullivan P, Elfenbein G. Dexamethasone, cyclophosphamide, idarubicin and etoposide (DC-IE): a novel, intensive induction chemotherapy regimen for patients with high-risk multiple myeloma. Brit J Haematol. 1997 Mar.96(4):746-748. Pubmedid: 9074417.
  • Crucian B, Moscinski L, Androlewicz M, Ballester O, Widen R, Yu H. Assessment of intracellular TAP-1 and TAP-2 in conjunction with surface MHC class I in plasma cells from patients with multiple myeloma. Brit J Haematol. 1997 Aug.98(2):426-432. Pubmedid: 9266943.
  • Moscinski L, Trudeau W, Fields K, Elfenbein G. High-sensitivity detection of minimal residual breast carcinoma using the polymerase chain reaction and primers for cytokeratin 19. Diagn Mol Pathol. 1996 Sep.5(3):173-180. Pubmedid: 8866230.
  • Moscinski LW, Pendergrass TW, Weiss A, Hvizdala E, Buckley KS, Kalina RE. Recommendations for the use of routine bone marrow aspiration and lumbar punctures in the follow-up of patients with retinoblastoma. J Pediat Hematol Onc. 1996 May.18(2):130-134. Pubmedid: 8846123.
  • Fields K, Elfenbein G, Trudeau W, Perkins J, Janssen W, Moscinski L. Clinical significance of bone marrow metastases as detected using the polymerase chain reaction in patients with breast cancer undergoing high-dose chemotherapy and autologous bone marrow transplantation. J Clin Oncol. 1996 Jun.14(6):1868-1876. Pubmedid: 8656255.
  • Gleeson N, Hill B, Moscinski L, Mark J, Roberts W, Hoffman M, Fiorica J, Cavanagh D. Urokinase plasminogen activator in ovarian cancer. Eur J Gynaecol Oncol. 1996.17(2):110-113. Pubmedid: 8654466.
  • Garland L, Ballester O, Vasey F, Benson K, Moscinski L, Farmelo M, Rodriguez M, Rapaport D. Multiple myeloma in women with silicone breast implants. Serum immunoglobulin and interleukin-6 studies in women at risk. Curr Top Microbiol. 1996.210:361-366. Pubmedid: 8565578.
  • Alkan S, Schnitzer B, Thompson J, Moscinski L, Ross C. Cyclin D1 protein expression in mantle cell lymphoma. Ann Oncol. 1995 Jul.6(6):567-570. Pubmedid: 8573535.
  • Agaliotis D, Papenhausen P, Moscinski L, Elfenbein G. Case report of spontaneous remission of cytogenetic relapse of chronic myelogenous leukemia suggestive of progression to blast crisis after allogeneic bone marrow transplantation. Ann Hematol. 1995 Jan.70(1):37-41. Pubmedid: 7827205.
  • Moscinski LC. The Role of Diagnostic Molecular Pathology in Detection of Minimal Residual Disease. Cancer Control. 1995 Jan.2(1):64-70. Pubmedid: 10887400.
  • Alkan S, Morgan M, Sandin R, Moscinski L, Ross C. Dual role for Afipia felis and Rochalimaea henselae in cat-scratch disease. Lancet. 1995 Feb.345(8946):385. Pubmedid: 7531265.
  • Williams L, Moscinski LC, Medveczky PG. Immunoglobulin germline mu transcripts in acute myelogenous leukemia cells vary in splicing pattern and are heterogeneous. Leukemia. 1995 Dec.9(12):2016-2022. Pubmedid: 8609711.
  • Fields K, Elfenbein G, Perkins J, Perkins J, Moscinski L. High dose versus standard dose chemotherapy for the treatment of breast cancer. A review of current concepts. Ann Ny Acad Sci. 1995 Dec.770:288-304. Pubmedid: 8597367.
  • Benaim E, Hvizdala E, Papenhausen P, Moscinski L. Spontaneous remission in monosomy 7 myelodysplastic syndrome. Brit J Haematol. 1995.89(4):947-948. Pubmedid: 7772545.
  • Moscinski L, Hill B. Molecular cloning of a novel myeloid granule protein. J Cell Biochem. 1995.58:1-12. Pubmedid: 8749713.
  • Spiers A, Saba H, Ballester O, Moscinski L, Morgan M, Williams E. Purple people with lymphoid neoplasms: a new clinical andpathological syndrome. Hematol Rev. 1995.9:197-204. Pubmedid: noPMID.
  • Moscinski LC, Ballester OF. Recent progress in multiple myeloma. Hematol Oncol. 1994 May.12(3):111-123. Pubmedid: 7525447.
  • Greene JN, Sandin RL, Fields KK, Moscinski LC, Beatty A, Pow-Sang J, Elfenbein GJ. Hemorrhagic Cystitis in Bone Marrow Transplant Patients: Is It an Infection or Chemotherapy Toxicity?. Cancer Control. 1994 Jul.1(4):411-415. Pubmedid: 10886995.
  • Moscinski L, Ballester O. Recent progress in multiple myeloma. Hematol Oncol. 1994.12:111-123.
  • Ballester O, Moscinski L, Lyman G, Chaney J, Saba H, Spiers A, Klein C. High levels of interleukin-6 are associated with low tumor burden and low growth fraction in multiple myeloma. Blood. 1994.83(7):1903-1908.
  • Greene J, Sandin R, Fields K, Moscinski L, Beatty A, Pow-Sang J, Elfenbein G. Hemorrhagic cystitis in bone marrow transplant patients: is it an infection or chemotherapy toxicity?. Cancer Control. 1994.1(4):411-415.
  • Wang X, Heller R, Cruse C, VanVoorhis N, Glass L, Fenske N, Berman C, Leo-Messina J, Rapaport D, Wells K, DeConti R, Moscinski L, Stankard C, Puleo C, Reintgen D. Detection of submicroscopic lymph node metasases with polymerase chain reaction in patients with malignant melanoma. Ann Surg. 1994.220:768-774.
  • Spiers A, Saba H, Vieson K, Ballester O, Moscinski L, Dinwoodie W. Mycosis fungoides and Sezary syndrome: treatment with carboplatin and etoposide by continuous intravenous infusion. Blood. 1994.84:169a-169a.
  • Williams L, Moscinski LC. Sterile transcription of immunoglobulin/T-cell receptor genes and other evidence of early lymphoid differentiation in acute myelogenous leukemia. Leukemia. 1993 Sep.7(9):1423-1431. Pubmedid: 8371592.
  • Virgilio JF, Moscinski LC, Ballester OF, Corrado C, Guida C, Balducci L, Saba H. Acute lymphocytic leukemia (ALL) in elderly patients. Hematol Oncol. 1993 May.11(3):121-126. Pubmedid: 8112726.
  • Moscinski LC, Naylor PH, Oliver J, Goldstein AL. Thymosin beta 4 synergizes with human granulocyte-macrophage colony-stimulating factor in maintaining bone marrow proliferation. Immunopharmacology. 1993 Jul.26(1):83-92. Pubmedid: 8407287.
  • Virgilio J, Moscinski L, Ballester O, Corrado C, Guida C, Balducci L, Saba H. Acute lymphoblastic leukemia (ALL) in elderly patients. Hematol Oncol. 1993.11(3):121-126.
  • Moscinski L, Naylor P, Oliver J, Goldstein A. Thymosin (beta)4 potentiates the action of human granulocyte-macrophage colony-stimulating factor on bone marrow proliferation. Immunopharmacology. 1993.26:83-92.
  • Ballester O, Moscinski L, Spiers A, Balducci L. Non-Hodgkin's lymphoma in the older person: a review. J Am Geriatr Soc. 1993.41:1245-1254.
  • Williams L, Moscinski L. Sterile transcription of immunoglobulin/T-cell receptor genes and other evidence of early lymphoid differentiation in acute myelogenous leukemia. Leukemia. 1993.7(9):1423-1431.
  • Gupta S, Spiers A, Saba H, Moscinski L, Lyman G, Diaz J, Trotti, III A, Ridley M, Endicott J, Sanderson R. Extranodal lymphomas of the head and neck (ELHN): A six-year survey. Blood. 1993.82(565a (Suppl 1)):2245.
  • Ballester O, Moscinski L, Morris D, Balducci L. Acute myelogenous leukemia in the elderly. J Am Geriatr Soc. 1992.40:277-284.
  • Moscinski L, Kasnic G, Saker A. The significance of an elevated serum lysozyme in acute myelogenous leukemia with eosinophilia. Am J Clin Pathol. 1992.97:195-201.
  • Ballester O, Saba H, Moscinski L, Nelson R, Foulis P. Pure red cell aplasia: treatment with intravenous immunoglobulin concentrate. Semin Hematol. 1992.29:106-108.
  • Ballester O, Moscinski L, Lyman G, Chaney J, Saba H, Spiers A, Klein C. Interleukin-6: a growth factor or a differentiation factor for multiple myeloma. Blood. 1992.80:483-483.
  • Moscinski LC, Nowell PC, Hoxie JA, Berger MS, Prystowsky MB. Surface marker analysis and karyotype distinguish acute biphenotypic leukemia from acute myelogenous leukemia expressing terminal deoxynucleotidyl transferase. Cancer. 1991 Nov.68(10):2161-2168. Pubmedid: 1913454.
  • Flannery MT, Wallach PM, Espinoza LR, Dohrenwend MP, Moscinski LC. A case of the eosinophilia-myalgia syndrome associated with use of an L-tryptophan product. Ann Intern Med. 1990 Feb.112(4):300-301. Pubmedid: 2297207.
  • Moscinski LC, So AL, Russell JE, Kant JA, Prystowsky MB. Myeloperoxidase-positive acute megakaryoblastic leukemia. Am J Clin Pathol. 1989 May.91(5):607-612. Pubmedid: 2541607.
  • Jaffe BD, Sabath DE, Johnson GD, Moscinski LC, Johnson KR, Rovera G, Nauseef WM, Prystowsky MB. Myeloperoxidase and oncogene expression in GM-CSF induced bone marrow differentiation. Oncogene. 1988 Feb.2(2):167-174. Pubmedid: 2835725.
  • Stork LC, Ambruso DR, Wallner SF, Sambrano JE, Moscinski LC, Wilson HL, McCabe ER. Pancytopenia in propionic acidemia: hematologic evaluation and studies of hematopoiesis in vitro. Pediatr Res. 1986 Aug.20(8):783-788. Pubmedid: 3737292.
  • Moscinski LC, Kleinschmidt-DeMasters BK. Primary eosinophilic granuloma of frontal lobe. Diagnostic use of S-100 protein. Cancer. 1985 Jul.56(2):284-288. Pubmedid: 3891065.
  • Landowski T, Moscinski L, Burke R, Buyuksal I, Painter J, Goldstein S, Dalton W. CD95 antigen mutations in hematopoietic malignancies. Leuk Lymphoma. 42(5):835-846. Pubmedid: 11697638.
  • Wiranowska M, Rojiani A, Gottschall P, Moscinski L, Johnson J, Saporta S. CD44 expression and MMP-2 secretion by mouse glioma cells: effect of interferon and anti-CD44 antibody. Anticancer Res. 20(6B):4301-4306. Pubmedid: 11205262.
  • Szakacs JG, Moscinski LC. Sequence homology of deoxyribonucleic acid to mouse mammary tumor virus genome in human breast tumors. Ann Clin Lab Sci. 21(6):402-412. Pubmedid: 1664195.
  • Hu X, Moscinski L, Hill B, Zuckerman K. 1996;3353.
  • Saba H, Nawab U, Nadeem S, Cosgrove D, Moscinski L, Spiers A, Balducci L, Lyman G, Zuckerman K. 1994;624a.
  • Moscinski L, Braylan R. Interpretation of modern diagnostic techniques in lymphoma. In: Rose N, De Macario E, Fahey J, Friedman H, et al, eds. Manual of Clinical Laboratory Immunology. 4th ed. Washington, DC: American Society For Microbiology Press; 1992;298-305.
  • Fields K, Elfenbein G, Perkins J, Moscinski L. High dose versus standard dose chemotherapy for the treatment of breast cancer: a review of current concepts. In: Sackstein R, Janssen W, Elfenbein G, et al, eds. Annals of the New York Academy of Sciences. New York, NY: 1995;288-304.
  • Fields K, Partyka J, Elfenbein G, Trudeau W, Kronish L, Perkins J, Moscinski L. Minimal residual disease in the bone marrow of patients with breast cancer undergoing bone marrow transplant: prognostic significance. In: Dicke K, Keating A, eds. Autologous Blood and Marrow Transplantation, Proceedings of the 8th International Symposium. Charlottesville, VA: Carden Jennings; 1997;305-312.
  • Fields K, Moscinski L, Hebel D, Perkins J, Elfenbein G. 1993;144.
  • Ballester O, Agaliotis D, Moscinski L, Fields K, Hiemenz J, Zorsky P, Goldstein S, Saba H, Spiers A. 1994;209.
  • Garland L, Ballester O, Vasey F, Benson K, Moscinski L, Farmelo J, Rodriguez M, Rapaport D. Immunology of Silicones. In: Potter M, Rose N, eds. Multiple myeloma in women with silicone breast implants. Serum immunoglobulin and interleukin-6 studies in women at risk. Berlin. Springer; 1996;361-366.

Patient Comments
Overall Satisfaction
0
★★★★★
★★★★★

0 patients rated this provider

The Provider Rating is an average of all responses to specific care provider-related questions from our nationally-recognized Press Ganey Patient Satisfaction Survey. These surveys assess the experience of our patients when visiting us for an Outpatient Clinic, Urgent Care or Virtual Health (Telemedicine) visit. Responses are measured on a scale of 1 to 5 with 5 being the best score.

Patients that are treated in outpatient or hospital environments may receive different surveys, and the volume of responses will vary by question.

Learn more about our patient satisfaction survey

Comments ()

Comments are gathered from specific care provider-related questions from our Patient Satisfaction Survey . The comments are submitted by patients and reflect their views and opinions. Patients are de-identified for confidentiality and patient privacy.

We post both positive and negative comments from the surveys. We do not post comments that are libelous, slanderous, profane, irrelevant or otherwise inappropriate or may risk the privacy of our patients. A “[…]” in the comments below indicates de-identified patient information or comments that are unrelated to the patient’s experience with the visit to the provider, such as comments related to another provider, about the survey itself, or otherwise completely off-topic.

Not all providers will have a star rating or comments. In order to ensure accuracy of our ratings, we only display ratings for providers who have a minimum of 30 completed from the previous 12 months.

Learn more about our patient comments

Provider Ratings and comments are gathered from our nationally-recognized Press Ganey Patient Satisfaction Survey. If a provider does not have ratings or comments listed it can be for several reasons, including:

  • The provider has not yet received the minimum number of patient satisfaction surveys to be eligible for display. We require a minimum of 30 surveys before we post results to ensure that the rating is statistically reliable and a true reflection of patient satisfaction.
  • He or she may be a researcher or other type of provider that does not see patients.
  • The provider practices in a specialty or office that does not use the specified surveys currently used for these ratings.
Learn more about our patient satisfaction survey, ratings and comments